Amy­lyx takes its ALS pro­gram to Nas­daq, rais­ing the stakes for the biotech's on­ly drug

The biotech that has gone all-in on ALS on its way to earn­ing one of the high­est neu­ro­science fi­nanc­ing rounds in the last five years is now ready to take the Nas­daq leap.

Amy­lyx Phar­ma­ceu­ti­cals filed its S-1 with the SEC late Thurs­day, pen­cil­ing in a $100 mil­lion raise es­ti­mate to help bring its on­ly prod­uct can­di­date to mar­ket. The move comes about five months af­ter Amy­lyx pulled in $135 mil­lion in a Se­ries C.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER